There are several FDA-approved prescription medications that may be considered by licensed providers for individuals with obesity, a high BMI, or weight-related health conditions
Figure 1 shows the most relevant aspects of the benefits/risks profile of GLP-1 RAs
What we therefore need is a medication that helps make glucose control easier and reduces the risk of obesity and the associated cardiovascular risk
doi:10.1016/j.bbagen.2012.10.012 Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL
Getting Started Hone is a comprehensive longevity platform that fixes symptoms and optimizes your life to increase your healthspan
A Map of the Category What Researchers Examine Across the Category Comparative GH-release potency across secretagogue sub-types Pulsatile versus sustained GH-secretion patterns Selectivity profiles (cortisol/prolactin off-target effects) GHRH-analog plus GHS-agonist synergy versus monotherapy Downstream IGF-1 responses Quality Considerations GH-secretagogue research depends on precise GH and IGF-1 readouts, so material purity and identity directly affect data reliability